Published in JAMA on February 05, 1992
Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ (1993) 0.83
Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun (1997) 0.83
Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. Arch Dis Child (1996) 0.83
The legacy of Edward Jenner. BMJ (1996) 0.82
Statement on Haemophilus influenzae type b conjugate vaccines for use in infants and children. CMAJ (1993) 0.77
Combined childhood immunizations. JAMA (1992) 0.75
The children's vaccine initiative: a public health solution or wishful thinking? Trans Am Clin Climatol Assoc (1994) 0.75
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54
Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. Infect Immun (1983) 12.81
Cholera. Clin Microbiol Rev (1995) 12.33
Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis (1987) 12.26
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
The diarrheal response of humans to some classic serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J Infect Dis (1985) 9.18
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis (1987) 8.19
Detection of an adherence factor of enteropathogenic Escherichia coli with a DNA probe. J Infect Dis (1985) 7.78
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J (1987) 7.15
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA (1992) 6.88
Plasmid-mediated adhesion in enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr (1983) 6.59
Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol Rev (1984) 5.98
Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic Escherichia coli. Infect Immun (1985) 5.42
Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J Infect Dis (1988) 5.30
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet (1990) 4.62
Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet (1997) 4.56
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest (1993) 4.53
Enteroaggregative Escherichia coli associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis (1989) 4.52
A sensitive and specific DNA probe to identify enteroaggregative Escherichia coli, a recently discovered diarrheal pathogen. J Infect Dis (1990) 4.43
Summary of an international workshop on typhoid fever. Rev Infect Dis (1986) 4.21
Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect Immun (1987) 3.96
A plasmid of enterohemorrhagic Escherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun (1987) 3.76
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect Immun (1992) 3.30
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis (1995) 3.14
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics (1998) 3.13
Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature (1984) 3.08
Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg (1978) 3.06
Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet (1984) 3.05
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet (1998) 2.98
Adsorption and growth of Vibrio cholerae on chitin. Infect Immun (1979) 2.90
From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on enteropathogenic Escherichia coli. J Infect Dis (1983) 2.71
Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol (1985) 2.66
Periodic fever syndrome in children. J Pediatr (1999) 2.62
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun (1977) 2.49
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli from patients with diarrhea. J Clin Microbiol (1990) 2.43
Experimental human infections with Giardia lamblia. J Infect Dis (1987) 2.42
Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae. Infect Immun (1984) 2.42
Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine (1991) 2.42
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest (1995) 2.41
Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAMA (1998) 2.37
Enteroaggregative Escherichia coli elaborate a heat-stable enterotoxin demonstrable in an in vitro rabbit intestinal model. J Clin Invest (1991) 2.35
Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol (1991) 2.34
Morphological studies on fimbriae expressed by Vibrio cholerae 01. Microb Pathog (1988) 2.33
Epidemiologic studies of Escherichia coli diarrheal infections in a low socioeconomic level peri-urban community in Santiago, Chile. Am J Epidemiol (1993) 2.31
Reduction of transmission of shigellosis by control of houseflies (Musca domestica) Lancet (1991) 2.30
Immunity to enterotoxigenic Escherichia coli. Infect Immun (1979) 2.30
Acellular pertussis vaccines for infants. N Engl J Med (1996) 2.29
Enteroaggregative Escherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin. Proc Natl Acad Sci U S A (1993) 2.28
An essential Saccharomyces cerevisiae single-stranded DNA binding protein is homologous to the large subunit of human RP-A. EMBO J (1990) 2.28
Hemagglutination and colonization factors in enterotoxigenic and enteropathogenic Escherichia coli that cause diarrhea. J Infect Dis (1980) 2.26
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun (1992) 2.23
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 2.20
Typhoid fever vaccines. Vaccine (1999) 2.18
Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis (1990) 2.18
Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet (1987) 2.17
Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J Infect Dis (1982) 2.14
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil. J Infect Dis (1982) 2.13
Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults. J Infect Dis (1976) 2.12
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis (1995) 2.10
Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect Immun (2001) 2.09
The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years. J Infect Dis (1996) 2.06
Viable but non-culturable Vibrio cholerae O1 revert to a cultivable state in the human intestine. World J Microbiol Biotechnol (1996) 2.05
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis (1994) 2.03
Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis (2000) 2.02
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun (1983) 2.01
Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis (1983) 1.94
Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis (1992) 1.94
Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis (1993) 1.93
Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection. Infect Immun (1998) 1.90
Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J (2001) 1.90
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis (1987) 1.90
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine (1990) 1.87
High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. Am J Trop Med Hyg (1996) 1.86
Purification, morphology, and genetics of a new fimbrial putative colonization factor of enterotoxigenic Escherichia coli O159:H4. Infect Immun (1987) 1.86
Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr (1992) 1.85
Chronic arsenic exposure and risk of infant mortality in two areas of Chile. Environ Health Perspect (2000) 1.85
Pertussis infection in adults with persistent cough. JAMA (1995) 1.84